Q-omics provides the consensus-scored SOWAHCP5 profile across patient tissues and cancer cell-line models. SOWAHCP5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, SOWAHCP5 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SOWAHCP5 RNA expression shows 7,524 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, COAD, and TGCT as cancer lineages where SOWAHCP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOWAHCP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOWAHCP5 survival associations across molecular data types. SOWAHCP5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOWAHCP5 RNA expression–survival associations across cancer types. High SOWAHCP5 expression shows unfavorable associations in KICH, UCS and UVM, but favorable associations in PAAD, SKCM and HNSC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for SOWAHCP5 RNA expression.
This table summarizes SOWAHCP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SOWAHCP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOWAHCP5 shows lower tumor expression in COAD, THCA and KICH and higher tumor expression in LUAD, BRCA and LUSC. The COAD box plot shows higher SOWAHCP5 RNA expression in normal versus tumor tissue (log2 FC = −0.136, t-test p < 0.001).
This table shows molecular features associated with SOWAHCP5 in patient tissues and cancer cell lines. In patient samples, SOWAHCP5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
